Treatment of resistant pulmonary tuberculosis in Hong Kong with regimens of second-line drugs.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury; D003523:Cycloserine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D005000:Ethionamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011605:Psychoses, Substance-Induced; D011718:Pyrazinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013828:Thioacetazone / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D011718:Pyrazinamide; D007612:Kanamycin; D003523:Cycloserine; D013828:Thioacetazone; D005000:Ethionamide